Brought to you by 
Endovasc, TissueGen form JV around drug-eluting stent; ended
16 May 2007
Executive Summary
Endovasc (cardiovascular and metabolic therapeutics) and TissueGen (drug-releasing bioresorbable polymer scaffolds) have formed a joint venture (Endovasc-TissueGen Research Sponsors LLC) to develop a bioresorbable drug-eluting cardiovascular stent to treat coronary artery disease.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
Deal Status
- Concluded
Deal Type
-
Alliance
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Endovasc, TissueGen form JV around drug-eluting stent; ended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice